OBJECTIVE: Signal transducer and activator of transcription 5 (STAT5) is a critical regulator of hematopoietic development and its impaired activation is associated with hematopoietic and immune cell defects. However, much of this information has been learned from knockout mice that still retain the potential for expression of STAT5 proteins that are N-terminally truncated due to alternative internal translation initiation codons. The goal of these studies was to use transplantation-based assays to analyze the degree of STAT5 deltaN activity in hematopoietic stem cells (HSC) and throughout lymphomyeloid development. METHODS: We have directly compared E14.5 fetal liver cells from mice with potential to express STAT5ab deltaN (STAT5ab(deltaN/deltaN)) with mice completely lacking STAT5a and STAT5b (STAT5abnull/null). We have also utilized retroviral complementation of STAT5abnull/null fetal liver HSC to enforce expression of full-length STAT5a or STAT5a lacking the first 136 amino acids (STAT5a deltaN). RESULTS: We report that STAT5 is required for HSC, lymphocyte, and erythrocyte development. We demonstrate that restored expression of STAT5a in STAT5abnull/null HSC provides a strong selective advantage, correcting T- and B-lymphocyte and erythrocyte development. Interestingly, Gr-1(+) blood cells were inversely correlated with B lymphocytes and both were normalized by STAT5a expression. In contrast, transduction of STAT5a deltaN only provided partial B-lymphocyte development. CONCLUSIONS: These studies define the role of STAT5 in maintaining normal lymphoid vs myeloid balance during hematopoiesis and highlight a major role for the N-domain in HSC function. The platform of retroviral complementation described here will be particularly useful for future studies to subdefine the N-domain regions that are critical for hematopoiesis.
OBJECTIVE:Signal transducer and activator of transcription 5 (STAT5) is a critical regulator of hematopoietic development and its impaired activation is associated with hematopoietic and immune cell defects. However, much of this information has been learned from knockout mice that still retain the potential for expression of STAT5 proteins that are N-terminally truncated due to alternative internal translation initiation codons. The goal of these studies was to use transplantation-based assays to analyze the degree of STAT5 deltaN activity in hematopoietic stem cells (HSC) and throughout lymphomyeloid development. METHODS: We have directly compared E14.5 fetal liver cells from mice with potential to express STAT5ab deltaN (STAT5ab(deltaN/deltaN)) with mice completely lacking STAT5a and STAT5b (STAT5abnull/null). We have also utilized retroviral complementation of STAT5abnull/null fetal liver HSC to enforce expression of full-length STAT5a or STAT5a lacking the first 136 amino acids (STAT5a deltaN). RESULTS: We report that STAT5 is required for HSC, lymphocyte, and erythrocyte development. We demonstrate that restored expression of STAT5a in STAT5abnull/null HSC provides a strong selective advantage, correcting T- and B-lymphocyte and erythrocyte development. Interestingly, Gr-1(+) blood cells were inversely correlated with B lymphocytes and both were normalized by STAT5a expression. In contrast, transduction of STAT5a deltaN only provided partial B-lymphocyte development. CONCLUSIONS: These studies define the role of STAT5 in maintaining normal lymphoid vs myeloid balance during hematopoiesis and highlight a major role for the N-domain in HSC function. The platform of retroviral complementation described here will be particularly useful for future studies to subdefine the N-domain regions that are critical for hematopoiesis.
Authors: M Kieslinger; I Woldman; R Moriggl; J Hofmann; J C Marine; J N Ihle; H Beug; T Decker Journal: Genes Dev Date: 2000-01-15 Impact factor: 11.361
Authors: Jonathan W Snow; Ninan Abraham; Melissa C Ma; Nancy W Abbey; Brian Herndier; Mark A Goldsmith Journal: Blood Date: 2002-01-01 Impact factor: 22.113
Authors: Kevin D Bunting; Heath L Bradley; Teresa S Hawley; Richard Moriggl; Brian P Sorrentino; James N Ihle Journal: Blood Date: 2002-01-15 Impact factor: 22.113
Authors: Ling Zhang; Donna B Badgwell; Jack J Bevers; Karni Schlessinger; Peter J Murray; David E Levy; Stephanie S Watowich Journal: Mol Cell Biochem Date: 2006-05-23 Impact factor: 3.396
Authors: H Dolznig; F Grebien; E M Deiner; K Stangl; A Kolbus; B Habermann; M A Kerenyi; M Kieslinger; R Moriggl; H Beug; E W Müllner Journal: Oncogene Date: 2006-05-11 Impact factor: 9.867
Authors: Katrin Friedbichler; Marc A Kerenyi; Boris Kovacic; Geqiang Li; Andrea Hoelbl; Saliha Yahiaoui; Veronika Sexl; Ernst W Müllner; Sabine Fajmann; Sabine Cerny-Reiterer; Peter Valent; Hartmut Beug; Fabrice Gouilleux; Kevin D Bunting; Richard Moriggl Journal: Blood Date: 2010-05-27 Impact factor: 22.113
Authors: Geqiang Li; Kristy L Miskimen; Zhengqi Wang; Xiu Yan Xie; Jennifer Brenzovich; John J Ryan; William Tse; Richard Moriggl; Kevin D Bunting Journal: Blood Date: 2009-12-14 Impact factor: 22.113
Authors: Andrea Hoelbl; Christian Schuster; Boris Kovacic; Bingmei Zhu; Mark Wickre; Maria A Hoelzl; Sabine Fajmann; Florian Grebien; Wolfgang Warsch; Gabriele Stengl; Lothar Hennighausen; Valeria Poli; Hartmut Beug; Richard Moriggl; Veronika Sexl Journal: EMBO Mol Med Date: 2010-03 Impact factor: 12.137
Authors: Fulu Liu; Ghada Kunter; Maxwell M Krem; William C Eades; Jennifer A Cain; Michael H Tomasson; Lothar Hennighausen; Daniel C Link Journal: J Clin Invest Date: 2008-03 Impact factor: 14.808
Authors: Lina Han; Albertus T J Wierenga; Marjan Rozenveld-Geugien; Kim van de Lande; Edo Vellenga; Jan Jacob Schuringa Journal: PLoS One Date: 2009-11-24 Impact factor: 3.240